Research + Expert Discussion
The Future of RWE
Virtual Event 2 of 2
-
June 23, 2026
-
2:00 PM ET
-
Webinar + Q&A
You'll benefit most if you are:
This session is designed for pharma brand teams, medical affairs leaders, RWE and outcomes research professionals, insights and analytics teams, and agency strategy leads working in rare disease or specialty therapeutics. It is especially relevant for teams evaluating how community-sourced data and AI can augment or extend their current evidence strategies.
Event Summary
The evidence landscape is shifting in ways that most 2024-era RWE programs were not designed to capture. Patient communities are generating structured, continuous signals about treatment experience, trust, and unmet needs. AI is making it possible to detect patterns in that data at a scale and speed that traditional study designs cannot match. And emerging models for patient participation in research are rewriting the rules of who contributes evidence, how, and on what terms.
Panelists will discuss what a new RWE framework could look like as advances in data analytics, community-driven insights, and evolving regulatory expectations become more integrated into current models. The conversation will also focus on the practical steps needed to get there, including building the right infrastructure, partnerships, and approaches to support the next generation of RWE.
Panelists
Four Themes
Trust as the new variable
Data from the Rare Trust Index shows how patient trust in AI, pharma, and research institutions is shifting. Trust is moving from a soft engagement metric to a hard evidence variable, heavily impacting future study design and clinical trial recruitment strategies.
Patient participation in research
Patient involvement is evolving beyond traditional enrollment. New frameworks emphasize patient contributed data, patient led research design, and compensation models that treat lived experience as a core, measurable research asset.
AI as infrastructure
Moving past the hype, AI serves as the infrastructure layer for next generation RWE. From natural language processing of patient narratives to automated community signal detection, AI is actively changing what counts as evidence and how fast it can be generated.
Real-time clinical trials
Traditional trial protocols break without continuous community data, AI powered monitoring, and active participants. Next generation designs leverage real time signal detection and synthetic control arms, showing exactly where community sourced data fits in.
Why Attend
- See proprietary data on how rare disease communities are already generating structured evidence signals
- Understand how AI is creating new categories of real-world evidence from patient community data
- Learn Why trust is emerging as a measurable variable in evidence generation and study design
- Hear diverse perspectives on where RWE infrastructure investment should go next
- Get a first look at findings from the Rare Trust Index exploring patient attitudes toward AI in research